Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

3107 - Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)


07 Oct 2016


Gynaecological cancers


Rebecca Kristeleit


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


R.S. Kristeleit1, R. Shapira-Frommer2, A. Oaknin3, J. Balmaña3, I.L. Ray-Coquard4, S. Domchek5, A.V. Tinker6, C.M. Castro7, S. Welch8, A.M. Poveda9, K. Bell-Mcguinn10, G. Konecny11, H. Giordano12, L. Maloney12, S. Goble13, L. Rolfe14, A. Oza15

Author affiliations

  • 1 Department Of Oncology, University College London, Cancer Institute, WC1E 6BT - London/GB
  • 2 Medical Oncology, Sheba Medical Center, 5262100 - Ramat Gan/IL
  • 3 Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 4 Department Of Oncology, GINECO, Centre Léon Bérard and University Claude Bernard, Lyon/FR
  • 5 Medical Oncology, University of Pennsylvania, Philadelphia/US
  • 6 Department Of Medicine, British Columbia Cancer Agency, Vancouver/CA
  • 7 Department Of Medicine, Gynecological Oncology, Massachusetts General Hospital, Harvard Medical School, Boston/US
  • 8 Division Of Medical Oncology, London Regional Cancer Program, London/CA
  • 9 Gynecology Department, Clinical Area Of Gynecologic Oncology, Valencian Institute of Oncology, Valencia/ES
  • 10 Gynecologic Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York/US
  • 11 Department Of Medicine, Hematology & Oncology, University of California Los Angeles (UCLA), Los Angeles/US
  • 12 Clinical Science, Clovis Oncology, Inc., Boulder/US
  • 13 Biostatistics, Clovis Oncology, Inc., Boulder/US
  • 14 Executive Vp Of Clinical And Preclinical Development, Clovis Oncology, Inc., Boulder/US
  • 15 Department Of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto/CA


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3107


Rucaparib has demonstrated clinical activity in BRCAmut HGOC in two phase 2 studies. Data from these studies were pooled to examine the clinical activity and safety of rucaparib in BRCAmut pts with HGOC who have received ≥2 prior chemotherapy (chemo) regimens.


Pts (n = 106) with BRCAmut relapsed, HGOC who received ≥2 prior chemo regimens and were enrolled in Study 10 part 2a (n = 42) or ARIEL2 part 1 or 2 (n = 64) by 1 Oct 2015 were included in the pooled efficacy analysis. The pooled safety dataset (n = 144) included 38 additional pts with


Median age was 59 years; median number of prior chemo regimens was 3. Median duration of treatment was 6.9 months. The investigator-assessed confirmed objective response rate (RECIST v1.1) was 54% in pts with ≥2 prior chemo regimens. The median duration of investigator-assessed confirmed response was 9.2 months (95% confidence interval: 6.6-11.7). Common treatment-emergent adverse events included asthenia/fatigue (78%; grade ≥3: 15%), nausea (76%; grade ≥3: 4%), anemia (51%; grade ≥3: 27%), vomiting (50%; grade ≥3: 6%), and transient increased ALT/AST (47%; grade ≥3: 13%). Five pts died as a result of disease progression.


Rucaparib has clinical activity and an acceptable safety profile in pts with BRCAmut HGOC who received ≥2 prior lines of chemo. The efficacy of rucaparib will be compared to standard chemo in a phase 3 study (ARIEL4).

Clinical trial identification

NCT01482715 (NIH), NCT01891344 (NIH)

Legal entity responsible for the study

Clovis Oncology, Inc.


Clovis Oncology, Inc.


R.S. Kristeleit: Consulting/Advisory role: Clovis Oncology, Roche/Genentech, Sotio, Lytix Biopharma; Travel, Accommodations, Expenses: Clovis Oncology, Basilea, PiQuR; Honoraria: Clovis Oncology, Roche/Genentech, AstraZeneca. A. Oaknin: Consulting or Advisory Role: AstraZeneca, PharmaMar, Clovis Oncology, Roche Glycart J. Balmaña: Consulting or Advisory Role - Clovis Oncology, Inc.; Speakers' Bureau: AstraZeneca; Travel Expenses: AstraZeneca. I.L. Ray-Coquard: Consulting or Advisory Role: PharmaMar, AstraZeneca, MSD, Roche Glycart; Travel, Accommodations, Expenses: PharmaMar, Roche Glycart. S. Domchek: Honoraria: EMD Serono; Research Funding: AstraZeneca, Clovis Oncology, Abbvie, Pharmamar. A.V. Tinker: Consulting or Advisory Role: AstraZeneca; Research Funding: AstraZeneca/MedImmune K. Bell-Mcguinn: Consulting or Advisory Role: Clovis Oncology, AstraZeneca; Travel, Accommodations, Expenses: Abbvie. G. Konecny: Consulting or Advisory Role: Novartis; Travel, Accommodations, Expenses: Novartis; Research Funding: Amgen, Pfizer. H. Giordano, L. Maloney, S. Goble, L. Rolfe: Employment: Clovis Oncology, Inc.; Stock and Other Ownership Interests: Clovis Oncology, Inc. A. Oza: Consulting or Advisory Role: Amgen, Verastem, Clovis Oncology, Immunovaccine; Travel, Accommodations, Expenses: AstraZeneca; Honoraria: WebRx; Research Funding: AstraZeneca, Roche, Merck, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings